Benzinga | Dec 4, 2020 08:04AM EST

I-Mab Highlights Advancement Of Clinical Development Of Anti-CD47 Monoclonal Antibody Lemzoparlimab In US And China

SHANGHAI and GAITHERSBURG, Md., Dec. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ:IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced the advancement of clinical development of the highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (also known as TJC4) in the US and China, achieving milestones as planned. The Company is progressing its US combination trial (NCT03934814), studying lemzoparlimab in combination with Rituxan(r) and Keytruda(r) in dose expansion cohorts in non-Hodgkin lymphoma (NHL) and advanced solid tumors, respectively. The combination study with Rituxan(r) will enroll NHL patients from both the US and China. Topline results from this study are expected next year.